{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:09:17Z","timestamp":1795140557592,"version":"4.10.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijantimicag.2024.107405","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:43:53Z","timestamp":1733532233000},"page":"107405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-517X","authenticated-orcid":false,"given":"Evdoxia","family":"Kyriazopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-099X","authenticated-orcid":false,"given":"Eleni","family":"Florou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-6762","authenticated-orcid":false,"given":"Elli","family":"Kouriannidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemis","family":"Bogosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Tsachouridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-8640","authenticated-orcid":false,"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-2266","authenticated-orcid":false,"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias C.","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Sympardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3077-4623","authenticated-orcid":false,"given":"Antonia","family":"Alevizou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5492-0760","authenticated-orcid":false,"given":"Alexia-Vasiliki","family":"Amvrazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9016-8169","authenticated-orcid":false,"given":"Errika","family":"Alexandrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyprianos","family":"Archontoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-7724","authenticated-orcid":false,"given":"Katerina","family":"Argyraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8297-2644","authenticated-orcid":false,"given":"Yakinthi","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Gkogka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Kyrailidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Kalyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triantafilli","family":"Nikolopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Bakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Karathanassiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Koklanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0253-7987","authenticated-orcid":false,"given":"Dionysios-Nikolaos","family":"Miletis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0982-5416","authenticated-orcid":false,"given":"Anna-Maria","family":"Tili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampros","family":"Vakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-9712","authenticated-orcid":false,"given":"Michael","family":"Samarkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-8446","authenticated-orcid":false,"given":"George","family":"Chrysos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyphallia","family":"Poulakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Metallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107405_bib0001","unstructured":"European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. 2021. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-use-kineret-adults-covid-19."},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0002","unstructured":"Fact sheet for healthcare providers: emergency use authorization for Kineret https:\/\/www.fda.gov\/media\/163075\/download."},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0003","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101785","article-title":"Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial","volume":"56","author":"Akinosoglou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0005","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0006","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/annrheumdis-2020-218694","article-title":"To immunosuppress: whom, when and how? That is the question with COVID-19","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0007","unstructured":"https:\/\/www.loimoxeis.gr\/covid-19-info-banner\/"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0008","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cmi.2020.06.018","article-title":"Clinical characteristics of COVID-19 patients in three consecutive generations of spread in Zhejiang, China","volume":"26","author":"Yao","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0009","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cmi.2020.06.033","article-title":"Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort","volume":"26","author":"Cheng","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0011","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc11463","article-title":"Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor","volume":"16","author":"Giamarellos-Bourboulis","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0012","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury. Reply","volume":"382","author":"Hayek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0013","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1681\/ASN.2020060829","article-title":"Soluble urokinase receptor (SuPAR) in COVID-19-related AKI","volume":"31","author":"Azam","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0015","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0016","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0017","first-page":"189","article-title":"Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19","volume":"10","author":"Siyer","year":"2023","journal-title":"North Clin Istanb"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0018","article-title":"A prospective cohort study of COVID-19: evaluation of the early role of IL-1 and IL-6 antagonists in improving the outcome of the illness and reduction in the risk of death","volume":"11","author":"Al Kharusi","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273202","article-title":"Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: a real world, retrospective cohort study","volume":"18","author":"Segala","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0020","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194462","article-title":"The effect of anakinra in hospitalized patients with COVID-19: an updated systematic review and meta-analysis","volume":"10","author":"Kyriakoulis","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0022","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1093\/rheumatology\/keab447","article-title":"Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"60","author":"Barkas","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0023","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3947\/ic.2021.0016","article-title":"The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of covid-19: a systematic review and meta-analysis","volume":"53","author":"Somagutta","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0024","doi-asserted-by":"crossref","first-page":"e2418","DOI":"10.1002\/rmv.2418","article-title":"Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Shang","year":"2023","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40001-023-01072-z","article-title":"Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"28","author":"Dahms","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0026","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2208872","article-title":"Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Lan","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0027","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000524560","article-title":"IL-1 mediates tissue-specific inflammation and severe respiratory failure in COVID-19","volume":"14","author":"Renieris","year":"2022","journal-title":"J Inn Immun"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1250483","article-title":"Anakinra authorized to treat severe coronavirus disease 2019: sepsis breakthrough or time to reflect?","volume":"14","author":"Shapiro","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107405_bib0029","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924003212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924003212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:25:47Z","timestamp":1736220347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924003212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0924857924003212"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107405","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107405"}}